PureTech Health

PRTC: 219.00 -23.00 (-9.50%) delayed: 15 Nov 2019, 17:30

Trade now
Bid Price 219.00 High Price 245.59
Ask Price 220.00 Low Price 192.29
Open Price 245.59 Spread 0.45%
Prev Close 219.00 Volume 258,436

PureTech Health Share Price

Historic - 6 months
>> Advanced PureTech Health Charts >>

PureTech Health Share Price Information

Name PureTech Health
Sector Biotechnology
Activites PureTech Health plc is an advanced biopharmaceutical company developing BIG medicines for dysfunctions of the Brain-Immune-Gut axis. The Company has gained deep insights into the connection between these systems and the resulting role in diseases that have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies with an unbiased, non-binary, and capital efficient R&D model across its affiliates and its internal labs. PureTech's affiliates include seven clinical-stage platforms, including one product that has been cleared by the US Food and Drug Administration (FDA) and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programmes. The PureTech Health pipeline includes ground-breaking platforms and therapeutic candidates that were developed in collaboration with some of the world's leading experts. PureTech's internal research and development is centred on tissue-selective immunomodulation for the treatment of oncology, autoimmune, and CNS-related disorders, with a near-term focus on targeting newly-discovered, foundational immunosuppressive mechanisms in oncology and novel approaches that harness the lymphatic infrastructure.
Index FTSE 250
Latest Share Price (p) 219.00 Net Gearing (%) 35.71
Market Capitalisation (£m) 690.34 Gross Gearing (%) 62.20
Shares in issue (m) 285.26 Debt Ratio 5.13
P/E Ratio -15.13 Debt-to-Equity Ratio 0.03
Total dividends per share (p) 0.00 Assets / Equity Ratio 2.65
Dividend Yield (%) 0.00 Price to book value 4.13
Dividend Cover 0.00 ROCE (%) -38.89
Earning per share (p) -16.00 EPS Growth (%) -23.08
52-week high / low (p) 307.00 / 155.50 DPS Growth (%) n/a

PureTech Health Broker Views

Date Broker Recommendation Price Old Target Price New Target Price Notes
15 Nov Liberum Capital Buy 219.00 347.00 - Reiterates
06 Nov Peel Hunt Buy 219.00 380.00 - Reiterates
04 Nov Peel Hunt Buy 219.00 380.00 - Reiterates
02 Oct Peel Hunt Buy 219.00 380.00 - Reiterates
23 Sep Peel Hunt Buy 219.00 380.00 - Reiterates
>> More PureTech Health Broker Views >>

PureTech Health Director Deals

Date Director Type Volume / Price Trade Value
15 Mar 2018 Dr John LaMattina Buy 43,000 @ 163.00p £70,090.00
14 Mar 2018 Dr Robert Langer Buy 4,300 @ 162.00p £6,966.00
03 May 2016 Dame Marjorie Scardino Buy 5,000 @ 1.35p £67.50
26 Oct 2015 Joi Ito Buy 6,650 @ 148.82p £9,896.53
09 Oct 2015 Dame Marjorie Scardino Buy 20,107 @ 127.20p £25,576.10
>> More PureTech Health Director Deals >>

PureTech Health News

>> More PureTech Health News >>